The latest price target for Predictive Oncology (NASDAQ:POAI) was reported by HC Wainwright & Co. on August 19, 2024. The analyst firm set a price target for $3.00 expecting POAI to rise to within 12 months (a possible 289.61% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Predictive Oncology (NASDAQ:POAI) was provided by HC Wainwright & Co., and Predictive Oncology initiated their buy rating.

There is no last upgrade for Predictive Oncology

There is no last downgrade for Predictive Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Predictive Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Predictive Oncology was filed on August 19, 2024 so you should expect the next rating to be made available sometime around August 19, 2025.

While ratings are subjective and will change, the latest Predictive Oncology (POAI) rating was a initiated with a price target of $0.00 to $3.00. The current price Predictive Oncology (POAI) is trading at is $0.77, which is within the analyst’s predicted range.